We identified a novel 14-bp heterozygous deletion that induced a frameshift mutation in exon 15 of SPAST (SPG4). This mutation is predicted to have functional impact and found to cosegregate with the disease phenotype.
INTRODUCTION
(c) hyperreflexia; and (d) extensor plantar response. (6, 7) Complicated HSP manifests other neurological or extraneurological abnormalities, such as mental retardation, deafness, cerebellar ataxia, epilepsy, dysarthria and ichthyosis. Although patients with pure HSP generally exhibit the disease's main clinical features, considerable variation is observed in the age of the patient at disease onset, as well as in the rate of progression and severity of spasticity within and between families. (1, 2, 6, 8) The SPG4 gene, which has been mapped to chromosome 2p21-p22, is the most common causative gene of autosomal dominant hereditary spastic paraplegia (ADHSP). Spastic paraplegia type 4 (SPG4) accounts for approximately 40% of AD pedigrees and 6%-15% of sporadic cases. (9) To date, more than 257 SPAST mutations have been reported, (10) including missense, nonsense or splice site mutations, small insertions or deletions, and large duplications or deletions. (11) (12) (13) (14) SPG4 encodes spastin, a 616 amino acid protein, which is a member of the AAA cassette (adenosine triphosphatases associated with diverse cellular activities). Spastin is a microtubule-severing enzyme (15) involved in remodelling protein complexes with adenosine triphosphate (ATP) hydrolysis and coordination of axonal microtubule interactions with the tubular endoplasmic reticulum network. (16, 17) In this context, we conducted a genetic study of a four-generation
Chinese family with ADHSP, investigating the SPAST gene via linkage analysis and direct sequencing methodologies.
ME THODS
The patients were from a Chinese family spanning four generations from Weihai, Shandong Province, China. HSP followed a pattern of AD inheritance in this family (Fig. 1) . The genetic METHODS A genetic study was conducted on a four-generation Chinese family with autosomal dominant HSP. The SPAST gene was investigated using linkage analysis and direct sequencing. Findings were compared with unaffected family members and 50 normal, unaffected individuals who were matched for geographical ancestry. Table I . Blood samples were obtained from 11 family members (symptomatic n = 4; asymptomatic n = 7) and one spouse (unaffected). Leucocyte genomic DNA was extracted using standard techniques.
We first tested whether HSP in the family was caused by a mutation in any of the known HSP loci. As SPG4 is the most common causative gene for ADHSP and SPG4 mutation accounts for approximately 40% of AD pedigrees, (9) we selected D2S2351 and D2S2347 (lying 0. 
RESULTS
The phenotype of the four patients (patients II3, II8, II10 and III1) who were found to have HSP was late disease onset (age ≥ 45 years) and severe clinical manifestations. Three patients (patients II3, II10 and III1) had severe symptoms, while patient II8 showed severe symptoms that were relatively fewer in number. Symptoms in the proband (patient II10), a 69-year-old woman, began at the age of 45 years, and included progressively spastic gait, walking difficulty that required assistance, tendon polymorphism found in the family.
Via Sanger sequencing, we were able to determine whether (19, 20) Most of the SPAST mutations reported include missense, nonsense or splice site mutations, small insertions or deletions, and large duplications and deletions. (11) (12) (13) (14) In our study, we detected a novel 14-bp heterozygous deletion (c.1630-1643delTACTCAGGAAGTGA) in exon 15 of the SPAST gene, which led to a frameshift mutation with a premature stop codon.
However, this mutation was found to be absent in 50 normal individuals who were matched for geographical ancestry.
Sequence analysis revealed the presence of the 14-bp deletion age-dependent or incomplete, or manifest subtle symptoms. (8, 9) Subtle symptoms may progress slowly and go unnoticed for years. The variation seen in exon 15 was at a highly conserved position, which predicted functional impact and cosegregation with the phenotype. Mutation (p.tyr544profsX28) between amino acids 544 and 571, with a premature termination, is predicted to disrupt the highly conserved functional domain (the AAA cassette), which includes the ATP binding and hydrolysis sites. (21) The likely pathogenic mechanism for the frameshift mutation in our study is haploinsufficiency, which leads to unstable mRNA levels and absence or low level of expression of proteins. (22) Although haploinsufficiency (loss-of-function mechanism) is currently the most accepted view, gain-of-function of a 'toxic' or dominant negative activity could also partly explain this pathogenic mechanism of SPAST mutation. (15, 16, 23, 24) Hence, the mechanism of HSP (via mutation in SPG4) is still a subject of much dispute.
In conclusion, we investigated the SPAST gene via linkage analysis and sequencing in a four-generation Chinese family who exhibited ADHSP. We found a novel mutation in exon 15
of the SPG4 gene in members of this family, which was absent in unaffected individuals who were matched for geographical ancestry. The mutation in a highly conserved AAA cassette spanning exon 7 to 16 was predicted to have functional impact and found to completely cosegregate with the HSP phenotype. Our result expands the mutation spectrum of SPG4.
The identification of this novel deletion in SPAST provides an opportunity to further study and increase our understanding of the mechanism of axonal neurodegeneration in HSP, which may have important therapeutic implications. As better understanding of the function of spasticity is important, further phenotypegenotype correlation studies will be required to help explain the variable expression of the SPG4 form for the prevention, diagnosis and treatment of HSP.
